AstraZeneca PLC has a budding oncology portfolio that includes four new medicines launched since 2015 and more on the way. The company is focused on competing against market-leading PD-1/L1s in lung cancer, expanding the PARP inhibitor Lynparza (olaparib) beyond women's cancer, building out a new hematology franchise and figuring out what combinations of drugs will provide the most durable benefits in the future.
The UK drug maker has a heritage in oncology and was ahead of its time with the launch of the targeted cancer drug Iressa (gefitinib) in 2003 – though it took time to clarify the drug’s role. But AstraZeneca has been better known for selling primary care blockbusters like Crestor and Nexium, both now generic, and Symbicort for asthma
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?